176 related articles for article (PubMed ID: 30150482)
1. Interactions between Cocaine and the Putative Allosteric Dopamine Transporter Ligand SRI-31142.
Moerke MJ; Ananthan S; Banks ML; Eltit JM; Freitas KC; Johnson AR; Saini SK; Steele TWE; Negus SS
J Pharmacol Exp Ther; 2018 Nov; 367(2):222-233. PubMed ID: 30150482
[TBL] [Abstract][Full Text] [Related]
2. Dual DAT and sigma receptor inhibitors attenuate cocaine effects on nucleus accumbens dopamine dynamics in rats.
Hersey M; Mereu M; Jones CS; Bartole MK; Chen AY; Cao J; Hiranita T; Chun LE; Lopez JP; Katz JL; Newman AH; Tanda G
Eur J Neurosci; 2024 May; 59(10):2436-2449. PubMed ID: 38444104
[TBL] [Abstract][Full Text] [Related]
3. Studies of the biogenic amine transporters 15. Identification of novel allosteric dopamine transporter ligands with nanomolar potency.
Rothman RB; Ananthan S; Partilla JS; Saini SK; Moukha-Chafiq O; Pathak V; Baumann MH
J Pharmacol Exp Ther; 2015 Jun; 353(3):529-38. PubMed ID: 25788711
[TBL] [Abstract][Full Text] [Related]
4. Amphetamine maintenance differentially modulates effects of cocaine, methylenedioxypyrovalerone (MDPV), and methamphetamine on intracranial self-stimulation and nucleus accumbens dopamine in rats.
Johnson AR; Banks ML; Selley DE; Negus SS
Neuropsychopharmacology; 2018 Jul; 43(8):1753-1762. PubMed ID: 29703999
[TBL] [Abstract][Full Text] [Related]
5. Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in rats.
Miller LL; Leitl MD; Banks ML; Blough BE; Negus SS
Pain; 2015 Jan; 156(1):175-184. PubMed ID: 25599313
[TBL] [Abstract][Full Text] [Related]
6. Behavioral and neurochemical effects of the dopamine transporter ligand 4-chlorobenztropine alone and in combination with cocaine in vivo.
Tolliver BK; Newman AH; Katz JL; Ho LB; Fox LM; Hsu K; Berger SP
J Pharmacol Exp Ther; 1999 Apr; 289(1):110-22. PubMed ID: 10086994
[TBL] [Abstract][Full Text] [Related]
7. Preference for distinct functional conformations of the dopamine transporter alters the relationship between subjective effects of cocaine and stimulation of mesolimbic dopamine.
Kohut SJ; Hiranita T; Hong SK; Ebbs AL; Tronci V; Green J; Garcés-Ramírez L; Chun LE; Mereu M; Newman AH; Katz JL; Tanda G
Biol Psychiatry; 2014 Nov; 76(10):802-9. PubMed ID: 24853388
[TBL] [Abstract][Full Text] [Related]
8. Development of long-acting dopamine transporter ligands as potential cocaine-abuse therapeutic agents: chiral hydroxyl-containing derivatives of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine.
Hsin LW; Dersch CM; Baumann MH; Stafford D; Glowa JR; Rothman RB; Jacobson AE; Rice KC
J Med Chem; 2002 Mar; 45(6):1321-9. PubMed ID: 11882001
[TBL] [Abstract][Full Text] [Related]
9. Cocaine-insensitive dopamine transporters with intact substrate transport produced by self-administration.
Ferris MJ; Mateo Y; Roberts DC; Jones SR
Biol Psychiatry; 2011 Feb; 69(3):201-7. PubMed ID: 20801429
[TBL] [Abstract][Full Text] [Related]
10. Relations between stimulation of mesolimbic dopamine and place conditioning in rats produced by cocaine or drugs that are tolerant to dopamine transporter conformational change.
Tanda G; Li SM; Mereu M; Thomas AM; Ebbs AL; Chun LE; Tronci V; Green JL; Zou MF; Kopajtic TA; Newman AH; Katz JL
Psychopharmacology (Berl); 2013 Sep; 229(2):307-21. PubMed ID: 23612854
[TBL] [Abstract][Full Text] [Related]
11. Abuse-Related Neurochemical Effects of Para-Substituted Methcathinone Analogs in Rats: Microdialysis Studies of Nucleus Accumbens Dopamine and Serotonin.
Suyama JA; Sakloth F; Kolanos R; Glennon RA; Lazenka MF; Negus SS; Banks ML
J Pharmacol Exp Ther; 2016 Jan; 356(1):182-90. PubMed ID: 26645638
[TBL] [Abstract][Full Text] [Related]
12. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters.
Shen HW; Hagino Y; Kobayashi H; Shinohara-Tanaka K; Ikeda K; Yamamoto H; Yamamoto T; Lesch KP; Murphy DL; Hall FS; Uhl GR; Sora I
Neuropsychopharmacology; 2004 Oct; 29(10):1790-9. PubMed ID: 15226739
[TBL] [Abstract][Full Text] [Related]
13. Applicability of the dopamine and rate hypotheses in explaining the differences in behavioral pharmacology of the chloro-benztropine analogs: studies conducted using intracerebral microdialysis and population pharmacodynamic modeling.
Othman AA; Newman AH; Eddington ND
J Pharmacol Exp Ther; 2007 Aug; 322(2):760-9. PubMed ID: 17519385
[TBL] [Abstract][Full Text] [Related]
14. Development of novel, potent, and selective dopamine reuptake inhibitors through alteration of the piperazine ring of 1-[2-(diphenylmethoxy)ethyl]-and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909).
Matecka D; Rothman RB; Radesca L; de Costa BR; Dersch CM; Partilla JS; Pert A; Glowa JR; Wojnicki FH; Rice KC
J Med Chem; 1996 Nov; 39(24):4704-16. PubMed ID: 8941383
[TBL] [Abstract][Full Text] [Related]
15. Allosteric modulatory effects of SRI-20041 and SRI-30827 on cocaine and HIV-1 Tat protein binding to human dopamine transporter.
Sun WL; Quizon PM; Yuan Y; Zhang W; Ananthan S; Zhan CG; Zhu J
Sci Rep; 2017 Jun; 7(1):3694. PubMed ID: 28623359
[TBL] [Abstract][Full Text] [Related]
16. Methylphenidate and cocaine self-administration produce distinct dopamine terminal alterations.
Calipari ES; Ferris MJ; Melchior JR; Bermejo K; Salahpour A; Roberts DC; Jones SR
Addict Biol; 2014 Mar; 19(2):145-55. PubMed ID: 22458761
[TBL] [Abstract][Full Text] [Related]
17. Changes in dopamine transporter and c-Fos expression in the nucleus accumbens of alcohol-tolerant rats.
Yoshimoto K; Ueda S; Nishi M; Yang Y; Matsushita H; Takeuchi Y; Kato B; Kawai Y; Noritake K; Kaneda S; Sorimachi Y; Yasuhara M
Alcohol Clin Exp Res; 2000 Mar; 24(3):361-5. PubMed ID: 10776677
[TBL] [Abstract][Full Text] [Related]
18. Lack of cocaine effect on dopamine clearance in the core and shell of the nucleus accumbens of dopamine transporter knock-out mice.
Budygin EA; John CE; Mateo Y; Jones SR
J Neurosci; 2002 May; 22(10):RC222. PubMed ID: 12006604
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters.
Dutta AK; Fei XS; Beardsley PM; Newman JL; Reith ME
J Med Chem; 2001 Mar; 44(6):937-48. PubMed ID: 11300876
[TBL] [Abstract][Full Text] [Related]
20. Oxygenated analogues of 1-[2-(Diphenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as potential extended-action cocaine-abuse therapeutic agents.
Lewis DB; Matecka D; Zhang Y; Hsin LW; Dersch CM; Stafford D; Glowa JR; Rothman RB; Rice KC
J Med Chem; 1999 Dec; 42(24):5029-42. PubMed ID: 10585212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
